Diagnosis and treatment agent Au (I)-AIEgens as well as preparation method and application thereof
By developing Au(I)-AIEgens, the problems of insufficient targeting and low phototherapy efficiency in existing cancer treatment methods were solved, and accurate killing and high-resolution imaging of tumor cells were achieved, with strong photostability and biological characteristics. Good compatibility and significantly improve the efficiency of phototherapy.
Patent Information
- Application Number
- CN202411066429.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-15
AI Technical Summary
Existing cancer treatment methods such as chemotherapy and traditional immunotherapy have problems such as insufficient targeting, high toxic side effects, strong resistance to drug resistance and low phototherapy efficiency. Commonly used photosensitizers have poor photostability in the clustered state, resulting in unsatisfactory treatment effect. .
Develop a diagnostic agent Au(I)-AIEgens, which induces luminescent material by introducing aggregation of Au(I) units, has a targeted endoplasmic reticulum targeting tumor cells, triggers endoplasmic reticulum stress, activates immune response, and generates through efficient ROS Achieve efficient tumor killing and have good fluorescence imaging characteristics.
Accurate targeted killing and high-resolution imaging of tumor cells, with strong light stability, good biocompatibility, short time consuming and easy operation, can significantly improve the phototherapy efficiency in the concentrated state, and be used in photodynamic therapy Implement self-report analysis during the process.
Smart Images

Figure CN118955538A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a diagnostic and therapeutic agent Au(Ⅰ)-AIEgens and a preparation method and application thereof. Background Art
[0002] Cancer is a major disease that threatens human health. It is characterized by high morbidity and mortality. In recent years, its morbidity and mortality have continued to grow worldwide. According to data released by the World Health Organization's International Agency for Research on Cancer (IARC), there were 19.29 million new cases of cancer and 9.96 million cancer deaths worldwide in 2020 alone. At present, cancer treatments mainly include: radiotherapy, surgical therapy and chemotherapy. To date, chemotherapy is still the main means of tumor treatment. It uses chemical drugs to inhibit the proliferation, infiltration and metastasis of tumor cells, thereby killing tumor cells, and has been widely used in the field of cancer treatment. However, this method still has many disadvantages in clinical use, such as: lack of tumor targeting, strong toxic side effects, and frequent use of chemotherapy drugs. Drug resistance. In order to improve the cure rate of cancer, many experts are still exploring and researching, but the treatment obstacles caused by the above-mentioned essential shortcomings have not yet been resolved. New, efficient and precise tumor treatment methods are still an urgent need at this stage.
[0003] In recent years, immunotherapy has gradually become a powerful means of tumor treatment as an emerging method. Cancer immunotherapy can track, kill and eliminate cancer cells by activating or enhancing the host's immune response. The advantage of immunotherapy is that it can not only eliminate local metastatic tumors, but also prevent tumor recurrence through long-term immune memory. However, traditional immunotherapy still has shortcomings, such as high price, obvious toxic side effects and low effective response rate, and the effect of single immunotherapy is limited. Therefore, some researchers have proposed that immunotherapy as a synergistic treatment combined with other treatment methods is expected to achieve more ideal results in tumor treatment. Phototherapy, as one of the important treatment methods of new treatment, has the advantages of non-invasiveness and few side effects. In addition, it has attracted much attention due to its unique immunogenicity. Studies have shown that phototherapy can induce tumor immunogenic death (ICD) under light irradiation using photosensitizers, promote the release of tumor-associated antigens in tumor cell residues, and further increase the activation, proliferation and infiltration of antigen-specific T cells. Therefore, combining phototherapy with immunotherapy can improve the effect of anti-tumor treatment. However, traditional photosensitizers have poor photostability, and most of them have severe aggregation fluorescence quenching (ACQ) in the aggregated state. In addition, the phototherapy effects of many traditional photosensitizers are also reduced due to the enhanced non-radiative attenuation caused by aggregation. In this case, aggregation-induced emission materials (AIEgens) provide an ideal solution for the development of phototherapy with significant therapeutic effects in the aggregated state due to their outstanding advantages such as strong emission in the aggregated state, strong photostability, and in vivo activation ability. More importantly, AIEgens also exhibit good fluorescence imaging properties, which can integrate diagnostic and therapeutic functions into one platform to achieve precise imaging-guided cancer treatment. However, the commonly used AIEgens still have defects such as poor light absorption and insufficient targeting, which lead to problems such as inefficient luminescence and limited phototherapy efficiency. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide a diagnostic and therapeutic agent Au(Ⅰ)-AIEgens and a preparation method and application thereof. The diagnostic and therapeutic agent Au(Ⅰ)-AIEgens provided by the present invention can not only target the endoplasmic reticulum of tumor cells and accurately kill tumor cells, but also achieve deep tissue penetration and high-resolution imaging.
[0005] In order to achieve the above object, the present invention provides the following technical solutions:
[0006] A diagnostic and therapeutic agent Au(Ⅰ)-AIEgens, wherein the diagnostic and therapeutic agent Au(Ⅰ)-AIEgens is an aggregation-induced emission material AIEgens into which an Au(Ⅰ) unit is introduced, and the structural formula thereof is shown in formula (Ⅰ):
[0007]
[0008] Among them, R1 is a substituted or unsubstituted straight chain, branched, cyclic alkyl chain with 1 to 20 carbon atoms, or a straight chain trimethylammonium with 1 to 20 carbon atoms, and the substitution is that one or more carbon atoms are replaced by oxygen atoms, alkenyl groups, alkynyl groups, aryl groups, carbonyl groups, hydroxyl groups, amino groups, carboxyl groups, cyano groups, nitro groups or ester groups; Ar1 is an aromatic ring; R2 is an electron-withdrawing group, a π bridge or H; Ar2 is hydrogen or a nitrogen aromatic ring; R3 is a carbene ligand, a phosphine ligand, or a pentafluorobenzene ligand; X1 is an anion; and the plurality is 2 to 20.
[0009] In certain embodiments, Ar1 is one of the following structural formulas 1 to 20; R2 is one of the following structural formulas 21 to 39; R3 is one of the following structural formulas 47 to 91; and X1 is one of the following structural formulas 92 to 98:
[0010]
[0011]
[0012] In certain embodiments, the diagnostic and therapeutic agent Au(I)-AIEgens may be one of the following structural formulas II to V:
[0013]
[0014] The present invention also provides a method for preparing the diagnostic and therapeutic agent Au(I)-AIEgens described in the above technical solution, wherein the structural formulas II to V comprise the following steps:
[0015] S1, triphenylamine and electron-withdrawing group or thiophene undergo Suzuki coupling reaction to obtain the first product;
[0016] S2, the first product is subjected to a Suzuki coupling reaction or a Knoevenagel reaction with pyridine boronic acid or p-methylpyridine to obtain a second product;
[0017] S3. The second product undergoes coordination reaction with triphenylgold chloride or carbene gold chloride to obtain the target product.
[0018] In certain embodiments, the ratio of triphenylamines to electron withdrawing groups or thiophenes in S1 is 1:1.2.
[0019] In certain embodiments, the ratio of the first product to pyridine boronic acid or p-methylpyridine in S2 is 1:1.2.
[0020] In certain embodiments, the ratio of the second product to triphenylgold chloride or carbene gold chloride in S3 is 1:2.
[0021] The present invention also provides a use of the diagnostic and therapeutic agent Au(I)-AIEgens described in the above technical solution in the preparation of anti-tumor drugs.
[0022] In certain embodiments, the Au(Ⅰ)-AIEgens can target the endoplasmic reticulum of tumor cells, cause endoplasmic reticulum stress, and trigger tumor-related immune response ICD. The present invention has no special limitation on the dosage form of the drug, and a medically acceptable dosage form of Au(Ⅰ)-AIEgens can be used. The present invention has no special limitation on the preparation method of the drug, and a preparation method of the corresponding dosage form can be used. The present invention has no special limitation on the content of Au(Ⅰ)-AIEgens in the drug, and the content of conventional active substances in the drug can be used.
[0023] The present invention also provides an application of the diagnostic and therapeutic agent Au(I)-AIEgens described in the above technical solution in the preparation of tumor cell and / or endoplasmic reticulum visualization products.
[0024] In certain embodiments, the product includes but is not limited to fluorescent dyes and photosensitizers. The present invention has no special restrictions on the preparation method of the product, and the preparation method of the corresponding product can be used. The present invention has no special restrictions on the content of Au(Ⅰ)-AIEgens in the product, and the content of conventional active substances in the product can be used.
[0025] Beneficial technical effects: The present invention provides a diagnostic and therapeutic agent Au(Ⅰ)-AIEgens, a preparation method and application thereof. The diagnostic and therapeutic agent Au(Ⅰ)-AIEgens of the present invention is an aggregation-induced luminescence material AIEgens in which an Au(Ⅰ) unit is introduced. The diagnostic and therapeutic agent has the characteristics of easy preparation, high fluorescence intensity, low fluorescence background, high biosafety, etc. It can be used to visualize tumor cells, and has the advantages of good photostability, good biocompatibility, short time consumption, simple operation, and wash-free imaging. It can realize self-reporting analysis of its own photodynamic therapy process and realize fluorescence imaging of tumor cells and organelles. In addition, Au(Ⅰ)-AIEgens achieves efficient tumor killing effect by targeting the endoplasmic reticulum and inhibiting TrxR to produce a large amount of ROS. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 is the compound 1 in Example 1 1 H NMR spectrum;
[0027] Figure 2 is the HRMS spectrum of compound 1 in Example 1;
[0028] Figure 3 is the compound 2 in Example 2 1 H NMR spectrum;
[0029] Figure 4 is the compound 2 in Example 2 13 C NMR spectrum;
[0030] Figure 5 is the HRMS spectrum of compound 2 in Example 2;
[0031] Figure 6 is the compound 3 in Example 3 1 H NMR spectrum;
[0032] Figure 7 is the compound 3 in Example 3 13 C NMR spectrum;
[0033] Figure 8 is the HRMS spectrum of compound 3 in Example 3;
[0034] Fig. 9 is the compound 4 in Example 4 1 H NMR spectrum;
[0035] Fig.10 is the compound 4 in Example 4 13 C NMR spectrum;
[0036] Fig.11 is the compound 4 in Example 4 31 P NMR spectrum;
[0037] Fig.12 is the HRMS spectrum of compound 4 in Example 4;
[0038] Fig.13 It is the UV-visible absorption graph of compound 1-4 in N,N-dimethylformamide-water mixed solution;
[0039] Figures 14 to 17 The fluorescence emission spectra of compounds 1-4 in N,N-dimethylformamide and water mixed solutions with increasing water content (a) and the fluorescence emission intensities of compounds 1-4 in different water / N,N-dimethylformamide mixed solvents (I) and in N,N-dimethylformamide (I0) (c, Fig.16 is the ratio of the embedded graph therein (I / I0) (b);
[0040] Fig.18 ROS generation ability of compounds 1-4;
[0041] Fig.19 The ability of compounds 1-4 to generate singlet oxygen;
[0042] Fig. 20 This is the laser confocal imaging effect of compound 1-4 on normal cells (HUVEC);
[0043] Fig.21 The laser confocal imaging effect of compound 1-4 on tumor cells (H292);
[0044] Fig. 22 This is the laser confocal co-localization analysis of compound 4 on different cell organelles;
[0045] Fig.23 To study the killing effect of compounds 1-4 on tumor cells (H292);
[0046] Fig.24 Detection of reactive oxygen species (ROS) generation of compounds 1-4 under different conditions. DETAILED DESCRIPTION
[0047] In order to better understand the present invention, the content of the present invention is further explained in conjunction with the following examples, but the content of the present invention is not limited to the following examples. The materials, reagents, etc. used in the examples and test examples of the present invention, unless otherwise specified, can be obtained from commercial channels; the methods used in the examples and test examples of the present invention, unless otherwise specified, are conventional methods.
[0048] Example 1 Preparation of Compound 1 (Structural Formula II)
[0049] The preparation of compound 1 is carried out according to the following reaction formula:
[0050]
[0051] Compound 1-a was prepared by the procedure described in the literature (L. Wang, X. Yang, S. Li, M. Cheng, L. Sun, RSC Adv. 2013, 3, 13677-13680);
[0052] (34.4 mg, 0.202 mmol) AgNO3 was dissolved in ethanol (20 mL), slowly added dropwise to a dichloromethane (10 mL) solution containing 1,3-bis(2,6-di-isopropylphenyl)iminoazole-2-gold (I) chloride (0.202 mmol, 100 mg), stirred at 600 rpm for 15 min at room temperature, then filtered with medium-speed filter paper into a dichloromethane solution (10 mL) containing compound 1-a (0.202 mmol) and NH4PF6 (0.202 mmol), and then continued to react at room temperature for 8 h. After the reaction was completed, filtered and concentrated, and recrystallized from dichloromethane (1 mL) / n-hexane (30 mL) to obtain product 1. Yield: 78%.
[0053] The structural characterization data of compound 1 are as follows: 1H NMR (400MHz, CDCl3) δ7.81(d,J=6.0Hz,2H),7.65(d,J=6.2Hz,2H),7.57(t,J=7.8Hz,2H),7.51-7.41(m,4H),7.32(dd,J =29.0,7.8Hz,8H),7.10(t,J=7.8Hz,6H),7.03(d,J=8.4Hz,2H),2.55(p,J=6.8Hz,4H),1.31(dd,J=27.4,6.8Hz,24H),( Figure 1 ).HRMS(MALDI-TOF):m / z:[MH-PF6] + Calculate for C 50 H 55 AuN4 + :908.4087; found:908.4042, ( Figure 2 ).
[0054] Example 2 Preparation of Compound 2 (Structural Formula III)
[0055] The preparation of compound 2 is carried out according to the following reaction formula:
[0056]
[0057] Compound 2-a was prepared by the procedure described in the literature (L. Fan, Q. Zan, X. Wang, S. Wang, Y. Zhang, W. Dong, S. Shuang, C. Dong, Chinese J. Chem. 2021, 39, 1303-1309);
[0058] AgNO3 (34.4 mg, 0.202 mmol) was dissolved in ethanol (20 mL), and slowly added dropwise to a dichloromethane (10 mL) solution containing 1,3-bis(2,6-di-isopropylphenyl)iminoazole-2-gold (I) chloride (0.202 mmol, 100 mg), stirred at 600 rpm for 15 min at room temperature, and then filtered with medium-speed filter paper into a dichloromethane solution (10 mL) containing compound 2-a (0.202 mmol) and NH4PF6 (0.202 mmol), and then continued to react at room temperature for 8 h. After the reaction was completed, the product was filtered and concentrated, and recrystallized from dichloromethane (1 mL) / n-hexane (30 mL) to obtain product 2. Yield: 76%.
[0059] The structural characterization data of compound 2 are as follows: 1H NMR (400MHz, CDCl3) δ7.71 (d, J=6.4Hz, 2H), 7.58 (t, J=7.8Hz, 3H), 7.53-7.39 (m, 6H), 7.35 (d,J=7.8Hz,4H),7.31-7.20(m,6H),7.17-6.98(m,8H),6.62(d,J=11.8Hz,1H),2.54(dt,J=
[0060] 13.6,6.8Hz,4H),1.30(dd,J=25.6,6.8Hz,24H),( Figure 3 ). 13 C NMR (100MHz, CDCl3) δ167.9,150.1,149.9,148.1,147.2,145.6,138.9,133.3,132.8,131.6 ,131.3,129.4,126.7,124.8,124.7,124.5,123.5,123.2,122.92,121.1,28.9,24.7,23.9,( Figure 4 ).HRMS(MALDI-TOF):m / z:[MH-PF6] + ,calcd for C 56 H 59 AuN4 + ,1016.4120; found:1016.4068,( Figure 5 ).
[0061] Example 3 Preparation of Compound 3 (Structural Formula IV)
[0062] The preparation of compound 3 is carried out according to the following reaction formula:
[0063]
[0064] Compound 3-a was prepared by the procedure described in the literature (X. Shi, SHP Sung, MMS Lee, RTK Kwok, Herman H. Y. Sung, H. Liu, JWY Lam, ID Williams, B. Liu, BZ Tang, J. Mater. Chem. B, 2020, 8, 1516);
[0065] (34.4 mg, 0.202 mmol) AgNO3 was dissolved in ethanol (20 mL), slowly added dropwise to a dichloromethane (10 mL) solution containing 1,3-bis(2,6-di-isopropylphenyl)iminoazole-2-gold (I) chloride (0.202 mmol, 100 mg), stirred at 600 rpm for 15 min at room temperature, then filtered with medium-speed filter paper into a dichloromethane solution (10 mL) containing compound 3-a (0.202 mmol) and 0.202 mmol of NH4PF6, and then continued to react at room temperature for 8 h. After the reaction was completed, filtered and concentrated, and recrystallized from dichloromethane (1 mL) / n-hexane (30 mL) to obtain product 3. Yield: 75%.
[0066] The structural characterization data of compound 3 are as follows: 1 H NMR(400MHz,THF-d8)δ8.42(d,J=5.4Hz,2H),8.22(d,J=7.6Hz,1H),8.13(d,J =6.8Hz,2H),7.98(dd,J=12.0,8.2Hz,3H),7.90(s,2H),7.60(t,J=7.8Hz,2H) ,7.45(d,J=7.8Hz,4H),7.28(t,J=7.8Hz,4H),7.21-7.10(m,6H),7.05(t,J=7 .4Hz,2H),2.71-2.65(m,4H),1.42(d,J=6.8Hz,12H),1.29(d,J=6.8Hz,12H)( Figure 6 ); 13 C NMR (100MHz, CDCl3) δ167.7,154.0,150.4,147.1,145.6,145.5,136.7,133.5,133.3,131.4,131.1, 131.0,130.2,129.4,126.2,125.2,124.8,124.7,124.6,124.4,123.7,122.2,28.89,24.76,23.95.( Figure 7 )HRMS(MALDI-TOF):m / z:[MH-PF6] + ,calcd forC 56 H 57 AuN6S + :1042.4025; found:1042.3960.( Figure 8 ).
[0067] Example 4 Preparation of Compound 4 (Structural Formula V)
[0068] The preparation of compound 4 is carried out according to the following reaction formula:
[0069]
[0070] Compound 4-a was prepared by the procedure described in the literature [X. Shi, SHP Sung, MMS Lee, RTK Kwok, Herman H. Y. Sung, H. Liu, JWY Lam, ID Williams, B. Liu, BZ Tang, J. Mater. Chem. B, 2020, 8, 1516];
[0071] AgNO3 (34.4 mg, 0.202 mmol) was dissolved in ethanol (20 mL), slowly added dropwise to a dichloromethane solution (10 mL) containing triphenylphosphine gold chloride (0.202 mmol, 125.5 mg), stirred at 600 rpm at room temperature, and then filtered with medium-speed filter paper into a dichloromethane solution (10 mL) containing compound 4-a (0.202 mmol) and KPF6 (0.202 mmol), and then continued to react at room temperature for 8 h. After the reaction was completed, filtered and concentrated, and recrystallized from dichloromethane (1 mL) / n-hexane (30 mL) to obtain product 4. Yield: 80%.
[0072] The structural characterization data of compound 4 are as follows: 1 H NMR(400MHz,THF-d8)δ8.92(d,J=6.6Hz,2H),8.65(d,J=6.6Hz,2H),8.37(d,J=7.6Hz,1H),8.01(dd,J=16.2,8.2Hz,3H), 7.72(dd,J=13.2,6.8Hz,6H),7.60(d,J=6.8Hz,9H),7.29(t,J=7.8Hz,4H),7.15(d,J=8.4Hz,6H),7.06(t,J=7.2Hz,2H)( Fig. 9 ); 13 C NMR(100MHz,THF-d8)δ155.1,154.5,152.4,149.9,148.6,137.1,135.6,135.4,133.5 ,132.2,131.5,131.1,130.8,130.6,130.4,129.2,128.5,127.9,126.7,124.6,123.3( Fig.10 ); 31 P NMR(162MHz,THF-d8)δ29.53,-135.28,-139.67,-144.06,-148.45,-152.84( Fig.11); HRMS(MALDI-TOF):m / z:[MH-PF6] + ,calcd forC 47 H 35 AuN4PS + :915.1980; found:915.1987( Fig.12 ).
[0073] Experimental Example 1 Characterization of Photophysical Properties of Compounds 1-4
[0074] (1) Using N,N-dimethylformamide (DMF) as solvent, prepare a final concentration of 2×10 -5 mol·L -1 The solution of compound 1-4 was placed in a cuvette, and its UV-absorption spectrum was detected using a Varian CARY 50 UV spectrometer. Fig.13 UV-visible absorption spectra of compounds 1-4 in N,N-dimethylformamide (DMF) / water mixed solutions with different water volume fractions.
[0075] (2) Since the compound is insoluble in water, water was used as a poor solubility to study the aggregation-induced emission effect. Water (H2O) and N,N-dimethylformamide (DMF) were mixed at different volume percentages (ratio of water to DMF: 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%), and the above mixture was used as a solvent to prepare a final concentration of 2×10 -5 mol·L -1 The solution of compound 1-4 was prepared and its fluorescence emission spectrum was detected by fluorescence spectrometer. Figures 14 to 17 The fluorescence emission spectra of compound 1-4 in a mixed solution of DMF and water with increasing water content and the ratio (I / I0) of the fluorescence intensity of compound 1-4 in different DMF / water mixed solvents (I) to that in DMF (I0) are shown.
[0076] Figures 14 to 17 It is shown that based on its absorption spectrum, compounds 1-4 are excited with 393nm, 450nm, 480nm, and 468nm light, respectively. With the addition of poor solvent (water), the luminescence of the resulting system gradually increases and reaches a maximum value when the water content is 90vol%, 99vol%, 90vol%, 90vol%, and 80vol%, respectively. In this process, we can observe that the maximum emission wavelengths of compounds 1-4 are 520nm, 620nm, 668nm, and 673nm, respectively, and the emission wavelength gradually red-shifts, which should be attributed to the combined effect of AIE and twisted intramolecular charge transfer (TICT) effect.
[0077] Compounds 1-4 have a typical donor-acceptor (DA) structure, which can achieve long-wavelength emission and efficient reactive oxygen species (ROS) production. The entire structural framework contains multiple flexible rotors or shakers connected by single or double bonds, thus ensuring the ideal AIE performance of compounds 1-4.
[0078] (3) DCFH-DA (2',7'-Dichlorodihydrofluorescein diacetate) was used as a ROS reactive oxygen species detection probe to detect the ROS generation of the synthesized compounds 1-4 in the solution (aggregate state). In the experiment, 10 μL of DCFH-DA activation solution (1.0 mM, NaOH was added to the DCF-DA ethanol solution for activation) was added to 2 mL of compound 1-4 (10 μM) solution, and white light (0.16 mW / cm -2 ) as the light source. The absorption values of DCFH-DA at 525 nm were recorded at different irradiation time periods. The results are shown in Fig.16 As shown in (a), when exposed to white light, compounds 1-4 can quickly and efficiently generate a large amount of ROS, and their production capacity is significantly better than that of the commercial photosensitizer Rose Bengal (RB) under the same conditions.
[0079] (4) ROS generation capability
[0080] The overall ROS-generating capacity of compounds 1-4 was evaluated using the commercial indicator 2,7-dichlorodihydrofluorescein (H2DCFDA). The PL intensity changes of H2DCF-DA at 525 nm were detected using a UV spectrophotometer in the presence or absence of the complexes and under light irradiation for different times (concentration: 10 μM) in PBS.
[0081] The results are as follows Fig.18 As shown. Under white light irradiation, all complexes can quickly and effectively generate ROS within 30s, and their generation capacity is significantly better than that of the commercial photosensitizer Rose Bengal (RB). Compound 3 exhibits the strongest ROS generation capacity, followed by Compound 2 and Compound 4.
[0082] (5) Singlet oxygen detection (anthracene dimethylmalonic acid ABDA method): ABDA (9,10-anthracene-diyl-bis(methylene)dimalonic acid) was used as a singlet oxygen detection probe. In the experiment, 10 μL of ABDA stock solution (7.5 mM) was added to 2 mL of compound 1-4 sample suspension (10 μM) respectively, and white light (0.16 mW / cm -2 ) as the light source. The absorption value of ABDA at 378nm was recorded at different irradiation time periods to obtain its decay rate during the photosensitization process. The results are shown in Fig.19 As shown, under white light irradiation, compounds 1, 2, 3, and 4 are generated. 1 O2 (singlet oxygen) is more powerful than RB. Although their singlet oxygen ( 1 There were some differences in the ability to generate ROS (O2), but compounds 3 and 4 showed the best performance, followed by compounds 2 and 1. The results show that the addition of thiophene and benzothiazole units to compound 1 makes compounds 2-4 have stronger ROS generation ability. We calculated the singlet oxygen quantum yields of compounds 1-4, and the values determined relative to RB are as follows: 0.98 times for compound 1, 1.03 times for compound 2, 5.82 times for compound 3, and 5.50 times for compound 4. Therefore, the singlet oxygen quantum yields of all four compounds are 0.98 times for compound 1, 1.03 times for compound 2, 5.82 times for compound 3, and 5.50 times for compound 4. 1 The O2 generation capabilities are far superior to RB.
[0083] Test Example 2
[0084] Cells (4T1 cells, mouse origin, purchased from Pronocell Life Science Co., Ltd.) were cultured in 35 mm confocal culture dishes at 5 × 10 4 The cells were cultured at a density of 10 cells / dish for 24 h. After replacing the cell culture medium, the cells were treated with 3 μM AIEgens for 30 min. For co-staining imaging, the cells were stained with ER Tracker TM Red, Mito Tracker TM Red and Lyso Tracker TM Red (Yeasen) was further treated and incubated. The cells were washed with phosphate buffered saline (PBS, pH = 7.4). Subsequently, they were imaged using a laser confocal microscope (Nikon A1HD25, Japan). For compounds 1 and 2: excitation wavelength: 405 nm; emission filter: 500 nm to 600 nm; for compounds 3 and 4: excitation wavelength: 488 nm; emission filter: 600 nm to 700 nm.
[0085] We evaluated the imaging performance of the complexes in normal cells. Fig. 20 As shown, there was no obvious fluorescence signal for all compounds in normal cells.
[0086] Tumor cells (H292, mouse origin, purchased from Pronocell Life Science Co., Ltd.) were incubated with compounds 1-4 respectively. The fluorescence imaging results are shown in Fig.21 As shown, all complexes exhibited significant imaging performance for tumor cells, while all complexes in normal cells had no obvious fluorescence signals, indicating that compounds 1-4 have imaging selectivity for tumor cells.
[0087] Laser confocal microscopy was used to evaluate the subcellular distribution of compounds 1-4. Fig. 22As shown, co-localization analysis with various subcellular structural probes revealed their enrichment in organelles. Notably, compound 4 showed excellent targeting ability to the endoplasmic reticulum (ER).
[0088] Test Example 3
[0089] Their cytotoxicity to various cancer cell lines was studied using the MTT assay. In the cell (H292 cells, mouse origin, purchased from Pronocell Life Science Co., Ltd.) viability assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used to assess the metabolic activity of the cells. The experiment was performed in a 96-well plate, with each well initially containing 6×10 3 After a 30-min incubation period, the plates were exposed to white light (72 J / cm 2 ) for 20 min, and another set of plates was kept in the dark as a control. After another 24 h of incubation, the culture medium in each well was replaced with 100 μL AIEgens suspensions of different concentrations (0 μmol / L, 1 μmol / L, 2 μmol / L, 3 μmol / L, 4 μmol / L, 5 μmol / L, 10 μmol / L). Subsequently, the cells were incubated for another 24 h. Next, 10% MTT reagent was added to each well, and the plates were incubated in an incubator at 37 ° C for 2 h. The absorbance of MTT at 560 nm was then measured using a microplate reader (Thermo Fisher Multiskan MK3, USA).
[0090] The results are as follows Fig.23 As shown. Compounds 1-4 showed obvious concentration-dependent cytotoxicity to 4T1 cells. Under white light irradiation, all compounds showed more obvious cell killing effects. In contrast, under the same conditions, compound 4 had the highest cytotoxicity, followed by compound 3, compound 2 and compound 1.
[0091] Test Example 4
[0092] 2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA) (Beyotime) was used to assess the level of intracellular reactive oxygen species (ROS). Cells (4T1 cells, mouse origin, purchased from Pronocell Life Science Co., Ltd.) were seeded in 35 mm confocal dishes and incubated for 24 h. Subsequently, the cells were stained with AIEgens (3 μM) for 30 min and then exposed to white light (72 J / cm 2 , 20 min) or placed in the dark. Afterwards, the cells were incubated with DCFH-DA (10 μM) for another 20 min. A laser confocal microscope (Nikon, Japan, excitation: 488 nm) was used to observe and capture the intracellular ROS level, and the Image J software was used to quantify the mean fluorescence intensity.
[0093] The ability of compounds 1-4 to generate ROS in situ in vitro Fig.24 As shown. The results showed that compounds 1-4 had different degrees of green fluorescence. In addition, it was observed that all compounds showed more obvious fluorescence under light irradiation. Overall, compound 4 showed the strongest ROS production ability under light irradiation.
[0094] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A diagnostic and therapeutic agent Au(Ⅰ)-AIEgens, characterized in that: The diagnostic and therapeutic agent Au(Ⅰ)-AIEgens is an aggregation-induced emission material AIEgens in which an Au(Ⅰ) unit is introduced, and its structural formula is shown in formula (Ⅰ): Among them, R1 is a substituted or unsubstituted straight chain, branched, cyclic alkyl chain with 1 to 20 carbon atoms, or a straight chain trimethylammonium with 1 to 20 carbon atoms, and the substitution is that one or more carbon atoms are replaced by oxygen atoms, alkenyl groups, alkynyl groups, aryl groups, carbonyl groups, hydroxyl groups, amino groups, carboxyl groups, cyano groups, nitro groups or ester groups; Ar1 is an aromatic ring; R2 is an electron-withdrawing group, a π bridge or H; Ar2 is hydrogen or a nitrogen aromatic ring; R3 is a carbene ligand, a phosphine ligand, or a pentafluorobenzene ligand; X1 is an anion; and the plurality is 2 to 20.
2. The diagnostic and therapeutic agent Au(Ⅰ)-AIEgens according to claim 1, characterized in that: Ar1 is one of the following structural formulas 1 to 20; R2 is one of the following structural formulas 21 to 39; R3 is one of the following structural formulas 47 to 91; X1 is one of the following structural formulas 92 to 98:
3. The diagnostic and therapeutic agent Au(Ⅰ)-AIEgens according to claim 1 or 2, characterized in that: The diagnostic and therapeutic agent Au(Ⅰ)-AIEgens can be one of the following structural formulas II to V:
4. A method for preparing the diagnostic and therapeutic agent Au(I)-AIEgens according to claim 3, characterized in that: The preparation of the structural formula II to V comprises the following steps: S1, triphenylamine and electron-withdrawing group or thiophene undergo Suzuki coupling reaction to obtain the first product; S2, the first product is subjected to a Suzuki coupling reaction or a Knoevenagel reaction with pyridine boronic acid or p-methylpyridine to obtain a second product; S3. The second product undergoes coordination reaction with triphenylgold chloride or carbene gold chloride to obtain the target product.
5. Use of the diagnostic and therapeutic agent Au(I)-AIEgens according to any one of claims 1 to 3 in the preparation of anti-tumor drugs.
6. Use of the diagnostic and therapeutic agent Au(I)-AIEgens according to any one of claims 1 to 3 in the preparation of tumor cell and / or endoplasmic reticulum visualization products.
7. The use according to claim 6, characterized in that: The products include but are not limited to fluorescent dyes and photosensitizers.
Citation Information
Cited By
Novel aggregation-induced emission substance targeted delivery triple therapy for tumor chemotherapy, radiotherapy and immunotherapy
CN116407545A
A novel aggregation-induced emission substance targeted delivery for tumor chemotherapy, radiotherapy and immunotherapy triple therapy
CN116407545B
Gold complexes with aggregation-induced emission characteristic as well as preparation method and application of gold complexes
CN120271627A
A type of gold complex with aggregation-induced emission properties and its preparation method and application
CN120271627B
